Sotalol is a prescription medication used to treat dangerous heart rhythm disorders. It has two FDA-approved uses: treating life-threatening ventricular arrhythmias (such as sustained ventricular tachycardia) and helping prevent the return of atrial fibrillation or atrial flutter in people with severe symptoms. It works in both adults and children.
How Sotalol Works
Sotalol is unusual among heart rhythm drugs because it works in two distinct ways at once. It functions as a beta-blocker, slowing the heart rate and reducing the force of each beat, which calms overactive electrical signals. At the same time, it blocks potassium channels in heart cells, which delays the time it takes for the heart’s electrical system to “reset” between beats. This dual action helps stabilize chaotic rhythms and keep the heart beating in a normal, regular pattern.
Because of this combination, sotalol is classified as both a Class II and Class III antiarrhythmic. Most beta-blockers don’t have this potassium-channel-blocking property, which is what makes sotalol specifically useful for rhythm control rather than just rate control.
Ventricular Arrhythmias
The first approved use is for documented, life-threatening ventricular arrhythmias, particularly sustained ventricular tachycardia. This is a condition where the lower chambers of the heart beat dangerously fast, potentially leading to cardiac arrest. Sotalol helps suppress these episodes and reduce their frequency.
One important caveat: sotalol has not been shown to improve survival in people with life-threatening ventricular arrhythmias. It controls the rhythm disturbance, but it doesn’t appear to reduce the overall risk of death from these conditions. This is a key distinction that factors into treatment decisions.
Atrial Fibrillation and Atrial Flutter
The second approved use is maintaining normal sinus rhythm in people who have already been converted out of atrial fibrillation or atrial flutter. In other words, sotalol doesn’t typically restore a normal rhythm on its own. Instead, it helps keep the heart in rhythm once it’s been corrected, delaying the time before the irregular rhythm comes back.
The FDA limits this use to people whose atrial fibrillation or flutter is “highly symptomatic,” meaning it significantly affects their quality of life. This restriction exists because sotalol itself carries serious risks, so the benefit needs to clearly outweigh the potential for harm.
In head-to-head trials, sotalol is effective but not the most powerful option available. In the SAFE-T trial, which compared sotalol, amiodarone, and placebo in 665 patients, the median time to atrial fibrillation recurrence was 74 days with sotalol versus 487 days with amiodarone and just 6 days with placebo. By one year, 68% of sotalol patients had experienced a recurrence compared with 48% on amiodarone. Sotalol clearly outperformed placebo, but amiodarone was substantially more effective at keeping patients in rhythm. However, amiodarone carries its own significant long-term side effects, so sotalol remains a reasonable first-line option for many patients.
Use in Children
Sotalol is approved for pediatric patients as well. In children, it’s most commonly used for supraventricular tachycardia, a fast heart rhythm originating in the upper chambers of the heart. A multicenter registry study found that intravenous sotalol was safe and effective for terminating or improving abnormal heart rhythms in 79% of pediatric patients, including those with congenital heart disease and severely reduced heart function.
Starting Sotalol Requires Hospitalization
Unlike most heart medications, sotalol is typically started in a hospital over a three-day period. This isn’t just a precaution. Sotalol can paradoxically cause the very type of dangerous heart rhythm it’s meant to prevent, a phenomenon called proarrhythmia. The most concerning form is Torsades de Pointes, a specific type of fast ventricular tachycardia linked to prolongation of the QT interval (the time it takes for the heart’s electrical system to recharge between beats).
During the hospital stay, your heart rhythm is continuously monitored on an ECG to make sure the QT interval doesn’t stretch into dangerous territory. If it does, the dose is reduced or the drug is stopped. This monitoring also happens with every dose increase, not just when you first start.
Serious Risks
Sotalol carries a boxed warning, the FDA’s most serious safety alert, for life-threatening proarrhythmia. The risk varies by patient group. In people with sustained ventricular tachycardia, the rate of Torsades de Pointes is about 4%. In people with less severe arrhythmias, that rate drops to roughly 1 to 1.5%. Patients who have both ventricular tachycardia and heart failure face the highest proarrhythmic risk, around 7%.
Several factors increase your risk of this complication: kidney problems (since sotalol is cleared through the kidneys), being female, taking higher doses, and having low potassium or magnesium levels. Low electrolyte levels must be corrected before starting the drug.
A Cochrane meta-analysis cited in the 2023 ACC/AHA atrial fibrillation guidelines found that sotalol was associated with roughly double the rate of all-cause mortality compared with controls. This finding is one reason current guidelines recommend reserving sotalol for patients whose symptoms are significant enough to justify the risk.
Who Should Not Take Sotalol
Sotalol is contraindicated in several groups. You should not take it if you have:
- Asthma: the beta-blocker component can trigger severe bronchospasm
- Slow heart rate (bradycardia) without a pacemaker in place
- Heart block without a pacemaker
- Uncontrolled heart failure
- Long QT syndrome or a baseline QTc above 450 milliseconds
- Severe kidney disease, since sotalol depends on the kidneys for elimination
- Sick sinus syndrome without a pacemaker
- Low potassium or magnesium levels that haven’t been corrected
Where Sotalol Fits Among Treatment Options
For atrial fibrillation rhythm control, the 2023 ACC/AHA guidelines position sotalol as one of several antiarrhythmic options. It’s effective but not the strongest. Amiodarone is more effective at maintaining sinus rhythm, but its long-term toxicity to the thyroid, lungs, liver, and eyes makes it a second-line choice for most patients. Sotalol is best avoided in people with heart failure and reduced pumping function, partly because most of those patients are already on a beta-blocker and adding sotalol’s beta-blocking effects is poorly tolerated.
For ventricular arrhythmias, sotalol is typically considered when other treatments haven’t worked or when an implantable defibrillator alone isn’t controlling frequent episodes. The choice between sotalol and other antiarrhythmics depends heavily on your specific heart condition, kidney function, and risk profile.